Full Coverage

Cilta-cel shows promise in treating multiple myeloma

Top news

Single-dose CAR-T therapy potentially curative in multiple myeloma

3 days ago

The New York Times

From No Hope to a Potential Cure for a Deadly Blood Cancer

5 days ago

By Gina Kolata

Israeli researchers help achieve breakthrough in myeloma treatment

3 days ago

Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma

16 hours ago

By Alexandra Gerlach

All coverage

Cilta-Cel Demonstrates "Curative Potential" in R/R Multiple Myeloma

18 hours ago

By Gina Mauro

FirstWord Pharma

Spotlight On: With GSK’s Blenrep waiting in the wings, J&J touts game-changing Carvykti data

2 days ago

By Simon King

Oncology News Central

Big Step Toward Finding the Cure for Multiple Myeloma? “Wonderful” Data at ASCO 2025

7 days ago

Clinical Trials Arena

ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups

8 days ago

By Frankie Fattorini

One-Third of Relapsed Multiple Myeloma Patients Achieve Five-Year Remission with Single Cilta-Cel Infusion

11 hours ago

Ciltacabtagene Autoleucel Delivers Lasting Remissions in Relapsed or Refractory Multiple Myeloma

5 days ago

🩸 Previously deadly blood cancer completely disappears in one-third of patients

Yesterday

evidencenetwork.ca

The Car-T have stopped the progression of multiple myeloma in a group of patients

3 days ago

Legend Biotech Reports Long-Term Progression-Free Survival Data for CARVYKTI® in Multiple Myeloma and Promising Early Results from New CAR-T Therapies in Solid Tumors

7 days ago

A Blood Cancer Was Thought Incurable—Until Now

3 days ago

By Arden Dier

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

6 days ago

By Gina Mauro

insights.citeline.com

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

6 days ago

By Alaric DeArment

Legend immunotherapy offers hope of cure for incurable blood cancer, NYT says

6 days ago

Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered lasting treatment-free remissions for at least five years in patients with relapsed or refractory multiple myeloma | JNJ Stock News

7 days ago

CARVYKTI shows lasting impact in multiple myeloma treatment

7 days ago

marketscreener.com

Legend Biotech Reports 5-Year Survival Data for Carvykti in Multiple Myeloma

7 days ago

The Manila Times

Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting

7 days ago

Johnson & Johnson’s Carvykti Shows Consistent Efficacy in Treating Multiple Myeloma Across Risk Groups

8 days ago

One-Third of Patients With Advanced Multiple Myeloma Achieve Five-Year Remission After Single Cilta-Cel Infusion

3 days ago

GenScript Biotech’s Associate Unveils Promising Long-term Cancer Treatment Data

6 days ago

Investing.com Australia

CARVYKTI shows five-year remission in myeloma study

7 days ago

Legend Biotech Reveals 5-Year Survival Data for CARVYKTI® at ASCO 2025

7 days ago

Legend Biotech unveils five-year survival data fro CARVYKTI

7 days ago

ASCO25: J&J’s Carvykti shows strong efficacy across multiple myeloma risk groups

8 days ago

By Frankie Fattorini

Search

Clear search

Close search

Google apps

Main menu